ABL Europe, University Clinic of Tuebingen and Prime Vector Technologies partner for a 2nd generation COVID-19 vaccine
ABL Europe uses viral vector expertise to collaborate with University Clinic of Tuebingen and Prime Vector Technologies for development and manufacture of its 2nd generation SARS-CoV-2 Vaccine Candidate
JUST – EVOTEC BIOLOGICS PARTNERS WITH ABL ON DEVELOPMENT OF BROADLY NEUTRALISING ANTIBODY AGAINST HIV
Just – Evotec Biologics, Inc. has entered into an agreement with Advanced BioScience Laboratories, Inc. (“ABL”), a global contract development and manufacturing organisation (“CDMO”) to the U.S. Government and biopharmaceutical industry.
Themis collaborates with ABL Europe to manufacture its SARS-CoV-2 Vaccine Candidate in France
ABL applies its expertise in custom manufacturing virus-based therapeutics to accelerate the Institut Pasteur and Themis’ coalition COVID-19 vaccine development
ABL Continues to Support Race to find a Cure; SARS-CoV-2 (COVID-19) Vaccine Candidate
ABL utilizes its expert bioanalytical services to support confidential clients’ COVID-19 vaccine development
ABL, Inc. Supports Fill/Finish of SARS-CoV-2 (COVID-19) Vaccine Candidate
ABL, Inc. utilizes its aseptic fill/finish facility to support confidential clients’ COVID-19 vaccine development
ABL, Inc. Awarded Multiple-Award IDIQ Contract to Provide cGMP Manufacturing Services in support of the PREVENT Cancer Preclinical Cancer Prevention Program – First Manufacturing Task Order Awarded
Advanced BioScience Laboratories, Inc. (ABL), a global contract development and manufacturing organization for biotherapeutics and vaccines, announced today that the company was awarded an Indefinite Delivery, Indefinite Quantity (IDIQ) contract by the National Cancer Institute (NCI) of the National Institutes of Health (NIH) under its PREVENT Cancer Preclinical Drug Development Program: cGMP Production of Vaccines and Biologicals for Cancer Prevention (Solicitation Number: N01CN87006-18). The 4-year multiple-award contract has a total program funding ceiling of approximately $50 million.
ABL Expands GMP Viral Vector Manufacturing Capacity with State-of-the-Art Facility Acquisition in Lyon, France
ABL is pleased to announce a strategic acquisition through its wholly-owned subsidiary, ABL Europe, of a 6,500 square meter GMP manufacturing site located in Lyon, France.
ABL, Inc. Announces Appointment of Jarlath Keating as President and Chief Executive Officer
ABL announces the appointment of Jarlath Keating as the new President and Chief Executive Officer of ABL, succeeding Dr. Thomas VanCott.
ABL Awarded Long-Running National Cancer Institute Contract to Continue Groundbreaking Retroviral Research
ABL is pleased to announce it was awarded the “Support for Research on Retroviral Pathogenesis, Treatment and Prevention” contract by the National Cancer Institute to conduct studies that advance the development of effective AIDS vaccines and other preventive therapeutic modalities.
ABL, Inc. Announces Hiring of Jarlath Keating as Chief Commercial Officer
ABL announces the hire of Jarlath Keating as Chief Commercial Officer. As CCO, Mr. Keating will report to the CEO and will head global Commercial Operations for ABL.
ABL, Inc. Announces Hiring of Marykay Marchigiani as Chief Financial Officer
ABL, Inc. announces the hire of Marykay Marchigiani as Chief Financial Officer (CFO).
Sartorius Stedim Biotech Supports ABL Europe in Successful Completion of Viral Vector GMP Capacity Expansion
Sartorius Stedim Biotech S.A. (SSB), a leading international technology partner of the biopharmaceutical industry, has been selected by ABL Europe as its primary supplier of single-use systems. Through a supply partnership with SSB, ABL Europe has successfully increased and brought online new viral vector manufacturing capacity at its European facility in Strasbourg.
Najít Technologies Partners with ABL for Development of Novel Vaccine Platform
ABL is working with Najít Technologies, Inc. to advance the development of Najít’s novel HydroVax™ vaccine platform. ABL will utilize its GMP manufacturing expertise for the advanced development of virus-based vaccine candidates to protect against a number of emerging and re-emerging infectious diseases.
ABL Europe Enters into a Collaboration for the GMP Manufacture of Hookipa Biotech’s Heterologous Viral Vector Immunotherapy Platform
Hookipa Biotech AG, a clinical stage biotech company aiming to develop best-in-class active immunization therapies for infectious diseases and oncology, and ABL Europe SAS, an ABL Inc. company providing dedicated viral vector GMP contract manufacturing (CMO) services for oncolytic, vaccine and gene therapy projects in all stages of clinical development through to commercial launch, have entered in a manufacturing collaboration.
ABL Europe and SillaJen Expand Strategic Manufacturing Collaboration for Oncolytic Virus Therapies
SillaJen, Inc., a clinical-stage, biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, and ABL Europe, an ABL, Inc. company providing dedicated viral vector GMP services for gene therapy, oncolytic products and vaccines for all stages of clinical supply, have expanded their strategic manufacturing collaboration.
ABL Awarded NIH Contract for HIV Vaccine Development Worth Up to $318 Million
ABL announced today it has been awarded the recompetition of the contract for “Preclinical Development Support” by the Division of AIDS (DAIDS) within the National Institute of Allergy and Infectious Disease (NIAID) of the National Institutes of Health (NIH). The contract will run for a total of seven years with a maximum funding level of $318 million.
ABL, Inc. is a Finalist for the Maryland Tech Council Life Science Company of the Year
The winner will be announced at the Maryland Tech Council’s Industry Awards Celebration on June 1, 2017 at the Bethesda North Marriott Hotel & Conference Center. This is the 29th year recognizing the highest achievers in the regional technology, life science and government contracting industries.
ABL Increases Aseptic Fill/Finish Capacity with State-of-the-Art, Fully Automated Vial Filling Line
ABL is proud to announce the successful expansion of its aseptic fill/finish operations at its Rockville, MD GMP biomanufacturing facility with the installation of a new, fully automated vial filling system.
The National Center for Advancing Translational Sciences (NCATS) Awards ABL a 5-Year Therapeutic Development and Manufacturing Contract
ABL, Inc. (ABL) was awarded contract #HHSN271201700010I from the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH), to provide “Contract Research Organization support for drug substance development and manufacture.” ABL will provide the Division of Pre-Clinical Innovation (DPI) at NCATS with a wide range of development and chemistry, manufacturing and control support services to advance promising therapeutics into clinical testing. This support will utilize ABL’s in-house translational research and Good Manufacturing Practice (GMP) capabilities for biologic protein and virus vector product development. Product types that may be developed under the program include recombinant proteins, monoclonal antibodies, gene therapies, vaccines, plasmids, small molecules and cellular therapeutics.
ABL Awarded BARDA Contract to Fill Live Virus-Based Medical Countermeasures
ABL, Inc. (ABL) has been awarded a five-year, indefinite delivery/indefinite quantity (ID/IQ) contract #HHSO100201600019I entitled “Respiratory Illness Live Virus Fill/Finish Services” by the Biomedical Advanced Research and Development Authority (BARDA) within the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS). The contract has a maximum ordering amount of $50 million and is part of a multiple award network to provide fill/finish capabilities for live virus-based medical countermeasure (MCM) product development towards licensure.
ABL Nominated for Two Vaccine Industry Excellence Awards: Best CMO & Best CRO
ABL announced today that they have been nominated for two Vaccine Industry Excellence awards, known as ViE awards. The goal of the ViE awards is to recognize industry leaders with the greatest achievements in the past 12 months within 10 categories. ABL is being considered for both the Best Contract Manufacturing Organization (CMO) and as Best Contract Research Organization (CRO).
ABL Awarded NIAID Contract to Develop Biotherapeutics to Address Infectious Disease
ABL announced it is one of four prime contractors awarded a ten-year, indefinite delivery/indefinite quantity (ID/IQ) contract #HHSN272201600004I “Preclinical Services for Biopharmaceutical Product Development” by the Division of Microbiology and Infectious Diseases (DMID) within the National Institute of Allergy and Infectious Disease (NIAID)
ABL Awarded Subcontract for the Production of an Inactivated Zika Virus Vaccine
ABL, Inc. announced it has been awarded a subcontract by Emergent BioSolutions Inc. for the rapid transfer and GMP production of an inactivated Zika virus vaccine. The Zika vaccine program is funded by the Biomedical Advanced Research and Development Authority and represents a critical response to the developing global risk of Zika infections.
The Division of AIDS Awards ABL a Seven-Year Contract to Provide HIV Microbicide Research and Product Development Support
ABL, Inc. is pleased to announce the award of contract #HHSN272201600008I for the “Comprehensive Resources for HIV Microbicides and Biomedical Prevention” (CRMP) by the Division of AIDS (DAIDS) in the National Institute of Allergy and Infectious Disease (NIAID).
ABL, Inc. Announces Agreements with REGENXBIO for Process Development, Scale-Up and Clinical Manufacturing of RGX-501
May 24, 2016 (Rockville, MD) – ABL, Inc. (ABL), a global contract research and manufacturing organization to the biopharmaceutical industry, today announced agreements with REGENXBIO, Inc., a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV® Technology Platform, to manufacture its lead product, RGX-501, for human clinical trials.
SillaJen Announces Commercial Manufacturing Agreement with ABL Europe For Lead Oncolytic Virus, Pexa-Vec
May 16, 2016 (San Francisco, Calif., USA and Strasbourg, France) –ABL to Provide Product for Ongoing Phase 3 Trial and Future Commercial Demand–
ABL Awarded 3-Year Program Extension as the Biologics Production Facility for NHLBI’s SMARTT Program
Rockville, MD—March 11, 2016 –- ABL is pleased to announce the National Heart, Lung and Blood Institute has awarded a three year extension for the Science Moving towards Research Translation and Therapy (SMARTT) program.
ABL Part of Team Awarded $900 Million IDIQ Contract by U.S. Army for Medical Product Research and Development
ABL, Inc. is pleased to announce it is a member of the Engility Corporation (formerly TASC, Inc.) team recently awarded a prime position supporting the Medical Product Research and Development (MPRD) contract for the U.S. Army Medical Research and Materiel Command.
ABL, Inc. Launches Virus Manufacturing Operations in Europe
Rockville, MD – February 18, 2016 – ABL, Inc. (ABL), a contract research and manufacturing organization to the biopharmaceutical industry, is pleased to announce the opening of its GMP virus manufacturing facility in Strasbourg, France.
Transgene and ABL Announce the Acquisition by ABL Europe of Transgene’s Production Asset
Strasbourg, France, and Rockville, MD – February 3, 2016 – Transgene SA (Euronext: TNG) a company specializing in immunotherapies, and ABL, Inc., a contract research and manufacturing organization, today announced the purchase by ABL Europe, a wholly owned subsidiary of ABL, of Transgene’s production asset situated in Illkirch, near Strasbourg. Transgene, ABL, Inc. and ABL Europe are all three members of the Institut Mérieux.
ABL, Inc. Offers Quanterix Diagnostic Platform for Ultrasensitive Biomarker Detection Through Platine Pharma Services Subsidiary
Rockville, MD – January 14, 2016 – Platine Pharma Services SAS (PPS), a majority owned subsidiary of ABL, Inc., is a preferred partner with Quanterix Corporation, providing new ultrasensitive assays using the single molecule measurement digital platform, Simoa.
ABL Named Small Business Champion by Montgomery County
Rockville, MD – July 10, 2015 – Thank you to Montgomery County Department of Economic Development for recognizing ABL as a Small Business Champion for the work we do to support our local small business community.
ABL Successfully Completes Drug Product Manufacture of Ebola Vaccine for Clinical Trial
Rockville, MD – June 30, 2015 – ABL, Inc. (ABL), a contract research and manufacturing organization to the biopharmaceutical industry, is pleased to announce the successful aseptic formulation and fill of an Ebola vaccine candidate for Emergent BioSolutions Inc. (EMERGENT).
ABL Awarded National Cancer Institute Contract to Continue Groundbreaking Retroviral Research
Rockville, MD – March 24, 2015 – ABL, Inc., a biomedical contract research and manufacturing organization to the biotechnology and pharmaceutical industries, is pleased to announce it was awarded contract # HHSN261201500001C for the “Support for Research on Retroviral Pathogenesis, Treatment and Prevention” by the National Cancer Institute (NCI).
ABL Recognized for Supporting Fill-Finish of Novavax’s Zaire Ebolavirus Glycoprotein Nanoparticle Vaccine
Rockville, MD – February 13, 2015 – The release of Novavax’s Zaire ebolavirus (EBOV) vaccine within three months from project initiation is described in BioProcessing Journal’s Spring 2015 article “Rapid Manufacture and Release of a GMP Batch of Zaire Ebolavirus Glycoprotein Vaccine Made Using Recombinant Baculovirus-Sf9 Insect Cell Culture Technology” (BioProcessing Journal, Hahn, Timothy, et al.).
ABL Selected to Support Glioblastoma Multiforme Trial with Clinical Testing Services
Rockville, MD – January 20, 2015 – ABL, Inc., a contract research and manufacturing organization to the biotechnology and pharmaceutical industry, is pleased to announce that its GCLP clinical laboratory team was recently selected to provide sample processing and screening services in support of a Ph II glioblastoma multiforme (GBM) immunotherapy trial for a confidential client.
Expression Therapeutics Selects ABL for Development of Hemophilia A Factor VIII Therapy
Tucker, GA and Rockville, MD (August 18, 2014) – Expression Therapeutics LLC, a biotechnology company developing high expression factor VIII technologies, together with ABL, Inc., a biomedical contract research and manufacturing organization to the biopharmaceutical industry, announced today an agreement whereby ABL will perform cell line development studies to improve manufacturability and reduce the costs associated with large-scale production of recombinant factor VIII replacement therapy.
ABL, Inc. Acquires Majority Interest in Platine Pharma Services
Rockville, MD, USA. ABL, Inc. (ABL), a biomedical contract research and manufacturing organization to the biopharmaceutical industry, is pleased to announce the acquisition of a majority interest in Platine Pharma Services (Platine), a specialist in immunomonitoring and immunogenicity services. With laboratories located in Lyon, France, Platine helps clients in the biopharmaceutical, food, cosmetic and diagnostic industries evaluate the immunogenicity, activity and efficacy of products during R&D, preclinical and human clinical studies.
ABL supports Profectus BioSciences with preclinical efficacy studies for its subunit vaccine for HIV, IHV001
Rockville, MD- ABL, Inc., a biomedical contract research and manufacturing organization to the biotechnology and pharmaceutical industry, has been selected by Profectus BioSciences, Inc. (Profectus) to evaluate different delivery regimens of one of its HIV vaccine candidates.
Dr. Thomas VanCott Invited to Speak at 11th Annual Biologics Forum in Tokyo
ABL’s President and CEO, Dr. Thomas VanCott, will attend the 11th Annual Biologics Forum in Tokyo, Japan on January 24, 2014. Dr. VanCott has been invited to speak at the conference on advances made in HIV vaccine research through projects performed at ABL.
Statement from ABL President and CEO Dr. Thomas VanCott on Strategic Agreement with Bioqual
Dr. Thomas VanCott, President and CEO of ABL, Inc. comments on the strategic agreement with BioQual, Inc. and ABL’s vision for growth.
ABL Completes Manufacture of Rhabdovirus-Based Oncolytic Therapeutic Vaccine for Phase I Clinical Trial
ABL, Inc. (ABL) has successfully delivered the final dosage form of a Rhabdovirus-based oncolytic therapeutic vaccine to the Ottawa Hospital Research Institute (OHRI). OHRI contracted ABL to execute fill finish operations for its Rhabdovirus therapeutic vaccine including clinical labeling under current Good Manufacturing Practices (cGMPs) for use in human clinical trials.
ABL, Inc. and CALIXAR Announce Strategic Marketing Agreement
Rockville, MD, USA and Lyon, France (October 30, 2013) – ABL, Inc. (ABL) today announced a co-marketing agreement with CALIXAR SAS (CALIXAR). Under the terms of the agreement, ABL will extend the capabilities of its vaccine and biologics therapeutic development services by offering CALIXAR’s innovative process for native extraction and purification of membrane proteins and antigens that avoid the necessity of re-folding and mutagenesis, while maintaining functionality, structural integrity and increasing product yield.
ABL Selected by PATH to Manufacture Novel Shigella Vaccine Candidate
Rockville, MD (October 1, 2013) – Advanced BioScience Laboratories, Inc. (ABL), a biomedical contract research and manufacturing organization to the biotechnology and pharmaceutical industries, announced today that it has been selected by PATH, an international nonprofit global health organization, to support the development and production of a novel Shigella vaccine candidate.
Dr. Maria Grazia Ferrari Spoke at the NMRC on Her Mucosal Immunology Research
On June 19th, Dr. Ferrari was an invited speaker for the ETEC Vaccine Program at the Naval Medical Research Center in Silver Spring, MD. Enterotoxigenic Escherichia coli (ETEC) is a common cause of bacterial diarrhea, which is a common ailment affecting deployed U.S. troops overseas and for which there is no vaccine.
ABL To Attend Biodefense Vaccines and Therapeutics Summit
ABL will be attending and exhibiting at the 11th Annual Emerging Diseases and Biodefense Vaccines, Therapeutics, and Diagnostics Summit in Washington, DC from June 17 to June 19.
ABL Awarded Simian Vaccine Evaluation Unit (SVEU) Contract with NIAID Worth Up To $80M
Advanced BioScience Laboratory, Inc. (ABL), a biomedical contract research and manufacturing organization to the biotechnology and pharmaceutical industries, announced today that it has been selected as one of three Simian Vaccine Evaluation Units (SVEUs) as part of a seven-year contract worth up to $80 million from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH).
ABL Wins 7-Year NIAID Simian Vaccine Evaluation Unit Contract
ABL won the 7-year contract to be one of three Simian Vaccine Evaluation Units (SVEU) for the National Institute of Health and Infectious Diseases (NIAID).
ABL President and CEO Dr. Thomas VanCott Named Finalist for Tech Council of Maryland (TCM) 2013 Executive of the Year
TCM’s annual Executive of the Year award recognizes innovative leadership in the Maryland Life Sciences and Technology communities. Dr. VanCott is a finalist for this year’s award, which will be announced at the TCM Annual Dinner and Tech Awards Celebration on May 16, 2013.
ABL President and CEO Dr. Thomas VanCott is a Finalist for Executive of the Year
ABL President and CEO Dr. Thomas VanCott is one of six finalists in the running for the Executive of the Year award from the Tech Council of Maryland (TCM) . The awards will be announced at the TCM Annual Dinner and Tech Awards Celebration on May 16, 2013.
ABL Recognized for Biologics Manufacturing in Support of NHLBI-Sponsored IND
In the latest issue of the National Heart Lung and Blood Institute’s (NHLBI) SMARTTnews, Dr. Steven Idell of the University of Texas Health Science Center expressed his appreciation of ABL’s biologics manufacturing team for creation of a master cell bank in support of his IND for a novel fibrinolysin, single chain urokinase plasminogen activator (scuPA).
ABL 2012 Publications and Presentations
In 2012, ABL staff had 12 presentations and publications based on research projects performed at ABL.
ABL Announces Additions to Manufacturing and Quality Control Teams
Rockville, MD, November 6, 2012 – Advanced BioScience Laboratories, Inc. (ABL) announces strategic hires in Upstream Process Development and Quality Control to further enhance its support of clients’ product development needs.
ABL Awarded NIH Contract to Fund up to $102M in Biologics Manufacturing and Characterization Services
Rockville, MD (August 1, 2012) – Advanced BioScience Laboratories, Inc. (ABL, Inc.) announced today the award of a contract to provide the NIH National Institute of Allergy and Infectious Diseases (NIAID) with preclinical development and cGMP manufacturing support for multiple vaccine and biologic products identified by NIAID Program staff.
ABL Awarded DMID Biologics Manufacturing Contract Worth Up to $102M
ABL was awarded a 10 year contract with the Division of Microbiology and Infectious Diseases (DMID) to provide “Manufacture and Characterization Services for Vaccines and Other Biologics for Infectious Diseases.”
ABL to Provide Cell Line Development, Process Development, and cGMP Manufacturing Services of scuPA for The University of Texas Health Science Center at Tyler
Rockville, MD (June 12, 2012) – Advanced BioScience Laboratories, Inc. (ABL) will perform process development and cGMP manufacturing of recombinant scuPA, an enzyme therapy candidate for patients with pleural loculation or scarring surrounding the lung. scuPA reverses a defect in clot clearance that characterizes pleural loculation. The program is led by Dr. Steven Idell of The University of Texas Health Science Center at Tyler in collaboration with Dr. Andrew P. Mazar and the Center for Developmental Therapeutics at Northwestern University in Evanston, IL.
ABL Supporting Manufacture of AlphaCores rhLCAT Protein through NHLBIs SMARTT Program
Ann Arbor, MI and Rockville, MD [February 14, 2012] – AlphaCore Pharma, a biopharmaceutical company, and Advanced Bioscience Laboratories (ABL), a biomedical contract research and manufacturing company, today announce funding from the National Institutes of Health, National Heart, Lung and Blood Institute (NHLBI) “Science Moving towards Research Translation and Therapy” (SMARTT) program, to manufacture recombinant human lecithin-cholesterol acyltransferase (rhLCAT) for the treatment of familial LCAT deficiency.
Inviragen Enlists ABL for Manufacture of Master Virus Seed Stock for Plague Vaccine Development
FORT COLLINS, CO and ROCKVILLE, MD – February 8, 2012 – Inviragen, Inc. and Advanced BioScience Laboratories Inc. (ABL), a biomedical contract research and manufacturing organization, today announced the signing of a contract manufacturing agreement between the two companies.
Trophogen Selects ABL as Contract Manufacturer for Recombinant, Human Follicle-Stimulating Hormone (rhFSH) Analog
Rockville, MD (January 10, 2012) – Trophogen Inc., a biotechnology company developing hormone and related growth factor analogs for human infertility, animal superovulation, and human cancers together with Advanced BioScience Laboratories Inc. (ABL), a biomedical contract research and manufacturing organization, today announced the signing of a contract manufacturing agreement between the two companies.
ABL Launches New Website
Rockville, MD (November 14, 2011) – Advanced BioScience Laboratories, Inc. (ABL), a leading biomedical contract research and manufacturing organization, is pleased to announce the launch of a newly redesigned website at www.ablinc.com.
ABL Awarded “NIAID Preclinical Development Support” Contract with Maximum Funding of $102M Over Seven Years
ROCKVILLE, MD (September 14, 2011) – The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded ABL with a contract to provide preclinical development support for promising candidates when such candidates emerge from the investigator-initiated research studies.
ABL Completes Validation of New cGMP Manufacturing Facility
ROCKVILLE, MD (August 28, 2011) — Advanced BioScience Laboratories, Inc. (ABL) announced today that its new cGMP biologics manufacturing facility located in Rockville, MD has completed validation and commenced cGMP operations in support of client projects.
ABL Selected to Collaborate on a 5-Year U19 Grant in Support of New Research toward an HIV Cure
Rockville, MD (July 20, 2011) – Advanced BioScience Laboratories (ABL) will provide nonhuman primate support and laboratory services for the Delaney AIDS Research Enterprise (DARE), Toward an HIV-1 Cure Project U19 grant entitled “Myeloid-T cell Interactions that Sustain HIV and SIV Reservoirs during Effective Antiretroviral Therapy.”
Contract Pharma: ABL Opens Newly Expanded HQ
Advanced BioScience Laboratories, Inc. (ABL) has opened its new research and manufacturing facility following the expansion of its vaccine and biotherapeutic product development capabilities at its new headquarters in Rockville, MD.
Washington Post – Biotech Consultants Find Fertile Ground in the DC Area
Rockville-based Advanced Bioscience Laboratories unveiled a 72,000-square-foot facility where its researchers plan to help other firms develop new drugs.
BioWatch: ABL Turns 50 with New Digs, Open House
Advanced Bioscience Laboratories, a contract research organization, marked its 50th anniversary with a new facility in Rockville.
ABL Inc. Awarded the NIH Contract for NHP Core Quantitative Viral RNA Laboratory for AIDS Vaccine Research and Development
Rockville, MD (March 30, 2011) – Advanced BioScience Laboratories, Inc. (ABL, Inc) was awarded the National Institutes of Health (NIH) contract for Nonhuman Primate (NHP) Core Quantitative Viral RNA Laboratory for AIDS Vaccine Research and Development in the amount of $6,892,113.
Advanced BioScience Laboratories Selected as the NHLBI Biologics Manufacturing Facility for New SMARTT Program
Kensington, MD (January 6, 2011) – Advanced BioScience Laboratories (ABL) has been awarded a contract with the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) to manufacture biologics for treatment and prevention of heart, lung, and blood diseases.